Market Overview - U.S. stock futures fell sharply on Monday following Friday's losses, influenced by the ongoing Iran-U.S. conflict and the death of Iranian Supreme Leader Ayatollah Ali Khamenei [1] - The Dow Jones, S&P 500, Nasdaq 100, and Russell 2000 indices experienced declines of -1.15%, -1.12%, -1.51%, and -1.36% respectively [3] Company Performance - AMTD Digital Inc. (NYSE:HKD) surged 20% in premarket trading after reporting a year-over-year increase in FY25 revenue [4] - Aardvark Therapeutics Inc. (NASDAQ:AARD) plunged 53.56% after pausing its Phase 3 trial, maintaining a weak price trend in the short and medium terms [4] - Avalon Globocare Corp. (NASDAQ:ALBT) tumbled 22.82% due to a private placement announcement, with a strong short-term price trend but weaker medium and long-term trends [4] - LI Bang International Corporation Inc. (NASDAQ:LBGJ) declined 24.85% after announcing an acquisition, showing a strong short and medium-term price trend but a weak long-term trend [4] - MongoDB Inc. (NASDAQ:MDB) dropped 2.27% as analysts expect earnings of $1.45 per share on revenue of $667.15 million [11] Economic Insights - Mohamed El-Erian warns of a "new stagflationary wind" affecting the global economy, driven by geopolitical shocks and persistent inflation [6] - The U.S. stock market is expected to experience volatility, dispersion, and fragmentation, with logistical friction from rising insurance premiums and maritime rerouting [7] - The market may face widening gaps between "winners and losers" as energy costs rise and growth encounters headwinds [8] Commodities and Global Markets - Crude oil futures rose by 7.71% to approximately $72.19 per barrel, while gold prices increased by 2.22% to around $5,395.00 per ounce [10] - The U.S. Dollar Index spot was up 0.66% at 98.2480, while Bitcoin traded 0.10% lower at $66,306.44 [10] Asian and European Markets - Asian markets closed mixed, with China's CSI 300 and Australia's ASX 200 rising, while Japan's Nikkei 225 and other indices fell [11]

Core Viewpoint - Avalon GloboCare Corp. has successfully closed a private placement, raising approximately $3.25 million, with potential additional proceeds of up to $6.5 million from warrants [1][3]. Group 1: Financial Details - The private placement involved the issuance and sale of 6,372,550 shares of common stock at a purchase price of $0.51 per share, along with Series A-1 and A-2 warrants [1]. - The gross proceeds from the offering were approximately $3.25 million before deducting fees and expenses, with potential additional gross proceeds of approximately $6.5 million if the warrants are fully exercised [3]. - The net proceeds from the offering will be used for debt repayment, working capital, and general corporate purposes [3]. Group 2: Warrants Information - Series A-1 warrants will expire five years from stockholder approval, while Series A-2 warrants will expire eighteen months from stockholder approval [1]. - The warrants have an exercise price of $0.51 per share and will be exercisable upon stockholder approval [1]. Group 3: Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and generative AI publishing and software [1]. - The company is advancing AI systems through its subsidiary, Avalon Quantum AI LLC, and is expanding its intellectual property in cellular therapy and generative AI [6]. - Avalon is also marketing the KetoAir™ breathalyzer device, registered as a Class I medical device with the FDA, and plans to pursue additional diagnostic applications [6].

Group 1 - Avalon GloboCare Corp. has entered into definitive agreements for the issuance and sale of 6,372,550 shares of common stock and associated warrants at a purchase price of $0.51 per share [1][3] - The offering is expected to generate approximately $3.25 million in gross proceeds before fees and expenses, with potential additional proceeds of about $6.5 million from the warrants if fully exercised [3] - The Series A-1 warrants will expire five years from stockholder approval, while the Series A-2 warrants will expire eighteen months from stockholder approval [1] Group 2 - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The securities are offered in a private placement under Section 4(a)(2) of the Securities Act and are not registered under the Act or applicable state laws, being available only to accredited investors [4] - The company plans to use the net proceeds for repayment of outstanding debt and for working capital and general corporate purposes [3][4] Group 3 - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and generative AI publishing and software [1][6] - The company is advancing AI systems through its subsidiary, Avalon Quantum AI LLC, and is also marketing the KetoAir™ breathalyzer device registered as a Class I medical device [6]

Avalon GloboCare (ALBT) shares more than doubled on Thursday after the diversified technology company said its subsidiary has been accepted into the Advanced Micro Devices (AMD) artificial intelligence (AI) Developer Program. This unexpected partnership with the semiconductor giant helped its share price breach the 20-day moving average (MA), signaling a shift in near term momentum. More News from Barchart Despite an explosive rally on Feb. 26, ALBT shares remain miles below its 52-week high. www.barc ...

Core Viewpoint - Avalon GloboCare Corp's stock is experiencing significant gains following its acceptance into Advanced Micro Devices Inc's AI Developer Program, indicating a strategic shift towards AI technology and potential growth opportunities in automated media production and enterprise applications [1][2]. Group 1: Company Developments - Avalon Quantum AI LLC, a subsidiary of Avalon GloboCare, has joined the AMD AI Developer Program, gaining access to various resources including AMD Developer Cloud credits and high-performance computing tools [2]. - The company plans to utilize these resources to enhance its automated commentary video engine, enterprise documentation tools, and AI-powered workflow automation platform [3]. - Interim CEO Meng Li emphasized that this program supports Avalon's transformation into a technology-focused AI company, positioning AQAI as a key growth driver [4]. Group 2: Product Innovations - Avalon is advancing its KetoAir product, a handheld breathalyzer aimed at ketogenic health management, which has recently renewed its registration with the U.S. Food and Drug Administration [4]. - The KetoAir device is expected to launch broader marketing efforts in the second quarter of 2026, with AQAI contributing to data-driven marketing and distribution strategies [5]. Group 3: Stock Performance - Avalon GloboCare's shares surged by 96.42%, reaching $1.00 at the time of publication, reflecting strong investor interest following the news of its partnership with AMD [6].

Strategic Access to AMD Developer Cloud Expected to Accelerate High-Performance AI Video Generation, and Future Enterprise Automation and Scalable DeploymentFREEHOLD, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced that it has been accepted into the Advanced Micro Devices (“AMD”) AI Developer Program, ...

Patent Covers Generation of Multiple Audience-Adaptive Commentary Video Variants While Preserving Factual IntegrityFREEHOLD, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced that its subsidiary, Avalon Quantum AI LLC, has filed a new U.S. provisional patent application covering an artificial intelligenc ...

Core Insights - The company has successfully converted the majority of its outstanding debentures, significantly strengthening its balance sheet and enhancing shareholder value [1][3][4] Financial Overview - The debentures originated from a June 2024 financing round with an aggregate principal amount of $2.8 million, of which $288 thousand was repaid in cash and $2.6 million was converted into common stock [2] - The conversion eliminates the majority of Avalon's outstanding debt, improving financial transparency and supporting long-term shareholder value creation [2][3] Strategic Implications - The conversion is viewed as a meaningful milestone that strengthens the company's capital structure, enhances capital efficiency, and improves overall financial flexibility [4] - This progress aligns with the company's recent return to compliance with Nasdaq's minimum stockholders' equity requirement, positioning it to execute strategic growth initiatives with greater confidence [4] Company Profile - Avalon GloboCare Corp. focuses on developing precision diagnostic consumer products and advancing intellectual property in generative AI publishing and software [5] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered as a Class I medical device with the U.S. FDA, and plans to develop additional diagnostic uses for this technology [5]

Core Viewpoint - The real estate sector has several oversold stocks that present potential buying opportunities for undervalued companies [1]. Group 1: Oversold Stocks - Douglas Emmett Inc (NYSE:DEI) has an RSI of 28.5, with a recent stock price of $10.55, down 2.3% on Monday, and a 52-week low of $10.52 [6]. - Hudson Pacific Properties Inc (NYSE:HPP) has an RSI of 28.2, with a recent stock price of $9.03, down 3.9% on Monday, and a 52-week low of $9.00 [6]. - Avalon Globocare Corp (NASDAQ:ALBT) has an RSI of 27.8, with a recent stock price of $0.81, down 0.9% on Monday, and a 52-week low of $0.78 [6]. Group 2: Analyst Downgrades - Scotiabank analyst downgraded Douglas Emmett from Sector Outperform to Sector Perform, reducing the price target from $16 to $12.5 [6]. - BMO Capital analyst downgraded Hudson Pacific Properties from Outperform to Market Perform, cutting the price target from $16 to $11 [6]. Group 3: Recent Developments - Avalon GloboCare announced the renewal of FDA establishment registration for its KetoAir device, which is a handheld breathalyzer for ketogenic health management [6].

Core Insights - The real estate sector has several oversold stocks that present potential buying opportunities for undervalued companies [1] Group 1: Oversold Stocks - Douglas Emmett Inc (NYSE:DEI) has an RSI of 28.5, with a recent stock price of $10.55, down 2.3% on Monday, and a 52-week low of $10.52 [6] - Hudson Pacific Properties Inc (NYSE:HPP) has an RSI of 28.2, with a recent stock price of $9.03, down 3.9% on Monday, and a 52-week low of $9.00 [6] - Avalon Globocare Corp (NASDAQ:ALBT) has an RSI of 27.8, with a recent stock price of $0.81, down 0.9% on Monday, and a 52-week low of $0.78 [6]